 ENGLEWOOD, Colo., June 25, 2021 PRNewswire -- Ampio Pharmaceuticals NYSE American: AMPE, a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced randomization and dosing of patients in its multi-center AP-019 Phase II clinical trial, using inhaled AmpionTM in the treatment of respiratory distress due to COVID-19, is underway. 